Another pembro punch.

This time smacking phospholipids. More and more autoimmune phenomena secondary to novel immunotherapies are coming to light. This case report details development of antiphospholipid syndrome in a patient receiving pembrolizumab for locally-advanced melanoma, clinically exhibited by Raynoud’s which completely resolved following discontinuation of pembro infusions. | Sanchez, JAMA Dermatol 2018